Title

Basal Bolus Versus Human Insulin in Hospitalized Patients With Diabetes in Paraguay
Basal Bolus Regimen With Insulin Analogs Versus Human Insulin in Medical Patients With Type 2 Diabetes: A Randomized Controlled Trial in Paraguay
  • Phase

    Phase 4
  • Study Type

    Interventional
  • Status

    Completed No Results Posted
  • Study Participants

    134
Few randomized studies have focused on the optimal management of non-ICU patients with type 2 diabetes in Latin America. Objective: Compare safety and efficacy of a basal bolus regimen with analogs and human insulins in general medicine patients admitted to a University Hospital in Asuncion, Paraguay.
Few randomized intervention inpatient trials have been conducted in Latin America to determine optimal treatment regimens for patients with type 2 diabetes. In the absence of regional guidelines, most international societies in Latin America recommend following international guidelines for the management of hospitalized patients with diabetes. However, hospital resources, admission cause and inpatient glycemic control differ among countries. In the US, the leading cause of admission to the hospital in patients with diabetes is cardiovascular disease, whereas infections and acute complications of diabetes are more common than cardiovascular disease in some countries. The safety and efficacy of insulin regimens in non-ICU setting in Latin countries have not been determined. Objective: to compare the efficacy and safety of a basal-bolus regimen using insulin analogs with glargine once daily plus glulisine before meals to human insulin with NPH twice daily and regular insulin before meals in medicine patients with type 2 diabetes Outcome measures. To determine differences in glycemic control between groups as measured by mean daily BG concentration during the hospital stay. Secondary outcomes included differences between treatment groups in any of the following measures: number of hypoglycemic events (BG <70 mg/dL and <40 mg/dL), total daily dose of insulin, length of hospital stay, hospital complications and mortality.
Study Started
Apr 30
2009
Primary Completion
Apr 30
2010
Study Completion
Mar 31
2011
Last Update
Oct 30
2014
Estimate

Drug Basal Bolus (Glargine and Glulisine)

Glargine daily + Glulisine before meals

  • Other names: Glargine and glulisine

Drug Human Insulin

NPH twice a day + Regular insulin before meals

  • Other names: NPH and regular

Basal Bolus (Glargine and Glulisine) Experimental

Basal bolus: with Insulin analogs (glargine and glulisine), 50% of total daily dose as glargine given before breakfast and 50% as glulisine insulin given in three equally divided doses before each meal.

Human Insulin Active Comparator

Human insulin: NPH and regular insulin: 2/3 of total daily dose as NPH and 1/3 as regular insulin. NPH insulin dose given as 2/3 in the morning before breakfast and 1/3 before dinner. Regular insulin given in three equally divided doses before each meal

Criteria

Inclusion Criteria:

Age >18 years
History of type 2 diabetes > 1 month
Treatment with diet alone, any combination of oral antidiabetic agents, and/or insulin prior to admission
Absence of diabetic ketoacidosis

Exclusion Criteria:

No history of diabetes
Subjects expected to undergo surgery during the hospitalization course
Clinically relevant hepatic disease
Impaired renal function (serum creatinine ≥ 3.0 mg/dL)
Pregnancy
Any mental condition rendering the subject unable to give informed consent
No Results Posted